Articles

Poll

Podcasts

Slideshows

Videos

Catch up on some of the biggest FDA news, clinical trial updates, and featured HCPLive coverage from the first half of 2026.


First Half 2026 Recap: Nephrology

The supplemental New Drug Application for Arcutis’ roflumilast cream 0.05% (Zoryve) is for mild to moderate atopic dermatitis in those down to 3 months.


FDA Accepts sNDA for Roflumilast Cream 0.05% in Infants Down to 3 Months with Eczema

Review the biggest gastroenterology news from the first half of 2026, including FDA updates, IBD advances, and key clinical trials.

First Half 2026 Recap: Gastroenterology

The FDA granted accelerated approval to atacicept to reduce proteinuria in adults with primary IgAN at risk for disease progression

FDA Approves Atacicept (Trutakna) for IgA Nephropathy

FDA grants Priority Review to Agios’ mitapivat sNDA for sickle cell disease, with a PDUFA date set for November 1, 2026.

FDA Grants Priority Review to Agios’ Mitapivat sNDA for Sickle Cell Disease

Here are 7 of the biggest nephrology stories from Q2 of 2026!


Q2 2026 Recap: Nephrology News & Updates

Phase 3 RAPIDe-3 data show rapid, sustained relief of hereditary angioedema attacks; PDUFA date set for April 23, 2027. 

FDA Accepts NDA for Oral Deucrictibant for HAE Attacks

A review of 9 novel drugs approved by the US Food and Drug Administration during the second quarter of 2026.

FDA News Recap: Novel Drug Approvals in Q2 2026

Exagamglogene autotemcel (Casgevy) is now the first CRISPR-based gene-editing therapy to reach this age group in either condition.

FDA Expands Exa-Cel Gene Therapy Approval to Children 2 Years and Up With SCD or β-Thalassemia

Catch up on the nephrology headlines you missed in June 2026. 